Novel polypeptides and intermediates for the preparation thereof



United States Patent 0 NDVEL POLYPEPTHDES AND INTERMEDIATES FOR THE PREPARATION THEREOF Roger Boissonnas, Bottmingen, and Ren Huguenin, Reinach, Basel-Land, Switzerland, assignors to Sandoz Ltd. (also known as Sandoz A.G.), Basel, Switzerland No Drawing. Filed Mar. 31, 11964, er. No. 356,026 Claims priority, application Switzeriand, Apr. 5, 1963,

4,361/63 7 Ciaims. or. zen-112.5

. 10 The present invention relates to a hitherto unknown polypeptide and its salts:

(IIH

Patented Jan. 1 7, i 1 967 The polypeptide I may be obtained by methods for the synthesis of peptides in actual use or described in the literature on the subject, it being possible to join together peroxide solution. Compound V may be obtained by reducing the nonapeptide derivative of Formula IV,

the amino acids in the order indicated in the above formula one at a time or by first forming constituent peptide units and joining these together until the polypeptide V (see below) results and oxidising this polypeptide V to form polypeptide 1.

One method of producing compound I comprises con- 0 R denotes a radical capable of protecting a sulfhydryl radical in peptide synthesis and R denotes a radical capable of protecting an amino radical in peptide synthesis, with an alkali metal, e.g. sodium or potassium, in liquid ammonia.

3 43. Compound IV may be obtained by condensing a hexatherapy of parenchymatous bleeding, whereby infiltrapeptide derivative of Formula II, tion of the tissues with compound I produces a pro- IYIHR (IJONIIz (5112 (EH: (EONHz SR (Ina-(EH2 (IJI'Iz II $11: (111:2 (I311: CH2 CIHz NI-I2-CHC ONI-ICHC O-NH-CH-C ON CIIC ONH-CHC o-Nu-orh-C ONHz Glu Asp Cys Pro Orn Gly in which R and R have the above significance, with a nounced ischaemic effect, The properties of compound I reactive derivative of a free acid of Formula III, are, furthermore, of especial use in surgery of the throat, CGHJOH Cum nose and ear, in gynaecology and obstetrics, in urology l I and dentistry.

fi r m 15 It is suggested that, when compound I is used in an RNHCHC NIICHC C 001I operation under local anaesthesia, it should be adminiscys Tyr Phe tered in admixture with the local anaesthetic, while when it is used in an operation under general narcosis, it should be administered in the form of a dilute physiological sodium chloride solution.

The process of the invention may be carried out, for example, as follows:

N-a-caPbobenzoxy-N-6-p-toluenesulphonyl L ornithine is condensed with glycine ethyl ester to give N-zxcarbobenzoxy-N-B-p-toluenesulphonyl L onithyl-glycine in which R and R" have the above significance.

Examples of radicals for protecting the amino radical 20 in the above process by temporarily blocking it are the carbobenzoxy, carbo p chloro benzyloxy, p-toluenesulphonyl and triphenylmethyl radicals, while examples of radicals for protecting the sulfhydryl radical are phenyl, benzyl, p-bromo-benzyl, p-chloro-benzyl, p-nitro-benzyl and p-xylyl radicals.

It has now been found that compound I has a vaso ethyl ester. After splitting off the carbobenzoxy radical, constrictive effect equal to that of the natural vasopressins the resulmlg N'5'p'toluenfisulphonyl L omlthylglyclne from which the new compound differs in that it contains elihyl ester 15 Condensed Wlth N'CEIFbObGHZOXY'L-PTOIWC an ornithine radical in the position of the lysine radical give Y- -P' Y 'P- p y (vasopressin from pigs, Formula VIa) or the arginine ornithyl-glycine ethyl ester, which is converted into the radical (vasopressin from cattle, Formula VIb), corresponding amide. After splitting off the carbobcnz- 'NCH-C ON1ICH-C ONlICl-Iz-C ONIIZ VI Pro X Gly Formula R X Compound VIa CH2CH CHg-CHz-NII Lys lysinc-vasoprcssin.

VII) CIT2-CHzCIlgN1IC-Nllg Arg arginine-vaso- H prcssin. NII

VIc=I CHz-CH2CH2NH 0m Polypeptide of Formula I.

However, in comparison with the natural vasopressins, oxy radical,the resulting L-propyl-N-E-p-toluenesulphonylcompound I has no antidiuretic action and is thus sug- L-ornithyl-glycinamide is condensed with N-carbobenzgested for use in therapy as a substance having a specific oxy-L-glutaminyl-Lasparaginyl-S-benzyl-L-cysteine azide vasoconstrictive effect. This specific vasoconstrictive to give N-carbobenzoxy L glutaminyl-L-asparaginyl-S- effect of compound I results from a direct influence on 5 benzyl L cysteinyl-L-propyl-N-fi-p-toluenesulphonyl-L- the vascular muscles; for this reason no appreciable side ornithyl-glycinamide. After splitting off the carbobenzeffects on the vegetative nervous system are produced, as oxy radical, the resulting L-glutaminyl-L-asparaginyl-S- is the case with adrenalin and noradrenalin. The selecbenzyl L cysteinyl-L-prolyl-N-6-p-toluenesulphonyl-L- tive vasoconstrictive effect of compound I could not be ornithyl-glycinamide is condensed with N-carbobenzoxyforeseen as the structure of the ornithine radical resembles S-benzyl-L-cysteinyl-L-tyrosyl-L-phenylalanine azide to the arginine radical and closely resembles the lysine radigive N-canbobenzoxy S benzyl-L-cysteinyl-L-tyrosyl-L- cal and it was thus to be expected that the properties of phenylalanyl L glutaminyl-L-asparaginyl-S-benzyl-L- the new compound I would not differ appreciably from cysteinyl L proyly-N-E-p-toluenesulphonyl-L-ornithylthose of the two natural hormones. The properties of glycinamide. This'nonapeptide derivative is treated with compound I are especially useful in the prophylaxis and an alkali metal, preferably sodium or potassium in liquid ammonia, so that the linear nonapeptide V results. This is converted by oxidation, preferably with air, oxygen or hydrogen peroxide in aqueous solution, into the biologically active, cyclic polypeptide I.

The hitherto unknown polypeptide I may be used as free base or as the salt of an organic or inorganic acid, either as pharmaceutical on its own or in the form of appropriate medicinal preparations for administration, e.g. parenterally, enterally or intranasally. Examples of acids for forming acid addition salts are hydrochloric, hydrobromic, sulphuric, fumaric, maleic, malic, acetic and tartaric acid, In order to produce such medicinal preparations, the compounds of the invention are worked up with organic or inorganic adjuvants which are inert and physiologically acceptable. Examples of such adjuvants are as follows:

Tablets and dragees: lactose, starch, talc and stearic acid.

Syrups: solutions of cane sugar, invert sugar and glucose.

Injectable solutions: water, alcohols, glycerin and vegetable 0115.

Suppositories: natural or hardened oils and waxes.

The preparations may furthermore contain suitable preserving, stabilizing or wetting agents, solubilizers, sweetening and colouring substances or flavourings.

The present invention also includes pharmaceutical compositions containing, in addition to a physiologically acceptable carrier, the compound I and/ or an acid addition salt thereof.

It should be noted that compound V above, together wit-h its acid addition salts and compounds II above, and also the free hexapeptide II (and its acid addition salts) wherein R and R" each represent a hydrogen atom, are included in the present invention as well as compounds IV above,

Examples of acids suitable for salt formation with compounds I and V and L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-ornithyl-glycinamide are hydrochloric, hydrobromic, sulphuric, citric, tartaric, succinic, maleic, malic, acetic, benzoic, hexahydrobenzoic, methanesulphonic, fumaric, gallic, and hydriodic acid.

In the following examples all temperatures are indicated in degees centigrade.

EXAMPLE 1 (a) N-a-carbobenzoxy-N-6-p-l0luenesuIphanyI-L- ornithyl-glycine ethyl ester 104 g". of N-a-carbobenzoxy-N-6-p-toluenesulphonyl-L- ornithine and 27 g. of glycine ethyl ester are dissolved in 450 cc. of acetonitrile, the mixture is cooled at 51 g. of dicyclohexyl carbodiimide are added and the mixture is shaken at room temperature for 4 hours. Precipitated dicyclohexyl urea is filtered off and washed with acetonitrile. The whole filtrate is evaporated in a vacuum. The residue crystallizes after the addition of petro leum ether. After recrystallization from n-propanol, 93 g. of N-e-carbobenzoxy-N-B-p-toluenesulphonyl-L-ornithyl-glycine ethyl ester are obtained; melting point 136; [a] =6.5 (96% ethanol).

(b) N -carb0benzoxy-L-prolyl-N -6-p-l0luenesulphonyl L-omithyl-glycinamide 90 g. of N-a-carbobenzoxy-N- p-toluenesulphonyl-L- ornithyl-glycine ethyl ester are dissolved in 800 cc. of anhydrous acetic acid which has been saturated with hydrogen bromide. The mixture is left to stand for one hour at evaporated in a vacuum at a temperature below 40 and the residue Washed carefully with diethyl ether. The residue is dissolved in 500 cc. of acetonitrile, cc. of triethylamine and 43 g. of N-carbobenzoxy-L-proline are added, cooling is effected at 0, 35.5 g. of dicyclohexyl carbodiimide are then added and the mixture shaken overnight at 20. After filtering off dicyclohexyl urea, the filtrate is evaporated in a vacuum at the residue. dissolved in ethyl acetate and this solution is washed with dilute sulphuric acid and aqueous ammonia. After drying over sodium sulphate, the ethyl acetate is removed by evaporation in a vacuum and the residue dissolved in 1 litre of absolute ethanol. The solution is cooled at 0, saturated with ammonia and left to stand overnight at 20. After evaporating in a vacuum at 30, the residue is recrystallized from dimethylformarnide/ethyl acetate. 58 g. of N-carbobenzoxy-L-prolyl-N-Ei-p-toluenesulphonyl- L-ornithyl-glycinamide are obtained; melting point 122 (with decomposition); [a] =46 glacial acetic acid).

(c) N-carboberzzoxy-L-glutamirzyI-L-asparaginyl-S-benzyl L cysteinyl L prolyl N 5 p loluenesulphonyl L-ornithyl-glycinamide g. of N-carbobenzoxy-L-prolyl-N-5-p-toluenesulphonyl-L-ornithyl-glycinamide are dissolved in 500 cc. of anhydrous acetic acid which has been saturated with hydrogen bromide, the solution is left to stand for one hour at 20 and is evaporated in a vacuum at a temperature below 40. The residue is carefully washed with diethyl ether and then added to a solution of 100 g. of N-carbobenzoxy- L-glutaminyl-L-asparaginyl-S-benzyl-L-cysteinyl-azide and 26 cc. of triethylamine in 1000 cc. of dimethylformamide. The mixture is left to stand overnight at 20, 3000 cc. of ethyl acetate are added thereto, the precipitate is filtered off and washing is effected with ethyl acetate. g. of N-carbobenzoxy-L-glutaminyl-L-asparaginyl-S-benzyl-L-cysteinyl-L-prolyl-N-fi-p-toluenesulphonyl L ornithyl-glycinamide are obtained; melting point 193; [a] =--38.5 (dimethylformamide).

(d) N carbobarzzoxy S benzyl L cysteinyl L tyrosyl L phcnyl alanyl L glutaminyl L asparaginyl S benzyl L -cysteilzyl L prolyl N 6 p-toluenesulph0nylL-orn[thyl-gIyci/zamide 50 g. of N-carbobenzoxy-L-glutaminyl-L-asparaginylS- benzyl-L-cysteinyl-L-prolyl-N-B-p-toluenesulphonyl-L ornithyl-glycinamide are dissolved in 250 cc. of anhydrous acetic acid which has been saturated with hydrogen bromide and the solution is left to stand for one hour at 20. After evaporating the solvent in a vacuum at a temperature below 40, the residue is carefully washed with diethyl ether and a solution of 31.5 g. of N-carbobenzoxy- S-benzyl-L-cysteinyl-L-tyrosyl-L-phenylalanine-azide and 7.5 cc. of triethylamine in 250 cc. of dimethylformamide is added thereto. The mixture is left to stand for 2 days at 20, 1000 cc. of ethyl acetate are subsequently added and the precipitate is washed With ethyl acetate. After drying in a vacuum at 30, the product is washed with Warm methanol. 45 g. of N-carbobenzoxy-S-benzyl-L- cysteinyl-L-tyrosyl-L-phenylalanyl L glutarninyl-L-asparaginyl-S-benzyl-L-cysteinyl-L-prolyl-N-B-p toluenesulphonyl-L-ornithyl-glycinamide are obtained; melting point 224; [a] =41 (dimethylformamide).

(e) L cysteinyl-L-Urosyl-L phonylalanyl-L-gluttaminyl- L-asparaginyl-L-cysteinyl-L-prolyI-L-ornithyZ- glycinamide The necessary amount of sodium or potassium metal is added to a solution of 5 g. of N-carbobenzoxy-S-benzyl- L cysteinyl-L-tyrosyl-L-phenylalanyl-L-glutaminyl L- asparaginyl-S-benzyl-L-cysteinyl-L-prolyl N 6 p toluenesulphonyl-L-ornithyl-glycinamide in 1200 cc. of dry liquid ammonia, whilst stirring at the boiling temperature of the solution, to give a stable blue colouration. After the addition of 3 g. of ammonium chloride, the solution is evaporated to dryness. The residue contains L-cysteinyl- L-tyrosyl L phenyl alanyl-L-glutaminyl-L-asparaginyl- L-cysteinyl-L-prolyl-L-ornithyl-glycinamide.

(f) Polypeptide compound I The residue obtained from step (e) above is dissolved in 5 litres of 0.01 N acetic acid and oxidized at a pH value 7 8 is brought to a pH value of 4.0-5.0 and after the addi- EXAMPLE 2 tion of 50 g. of sodium chloride or 0.6-4 g. of methanesulphonic acid evaporation to dryness is effected, where- Th am p ocedure as in Example 1 is used, except that by a dry powder results which keeps well. It may be final oxidation is effected at -40 by the addition of stored and when used it may be dissolved to give a clear 5 CC- Of a N solution of hydrogen peroxide in water solution. However, the solution may also be used as at a P Value Of (instead of Oxidation y introsuch, if desired after diluting with water or a salt soluduclng air or oxygen). tion. What we claim is:

In paper chromatography and paper electrophoresis 1. A compound selected from the group consisting of the polypepetide compound I proved to be homogeneous. a polypeptide f h f0rml1l $ONI'I; (IIGILOH (F6115 CH2 CONHz CH2 (3H2 ([111: $112 NIL-([JH-C ONII( :H-c ONII--CHC ONHCI-IC O-NII-CH-C ONIICIZHO 0 (5B2 (II-H2 II S 5 ll Oys Tyr Phe Glu Asp Cys l NH,

I I i C1'IzCIIg $112 I CH1 CH2 'N-CHC ONI'ICHC ONH-CHz-C ONl-Iz Pro Orn Gly and its pharmaceutically acceptable acid addition salts.

2. A compound selected from the group consisting of In the high tension electrophoresis on paper the polypeptide I wanders at a pH value of 5.8 (pyridine/ acetic acid/ water 9: 1:90) of the distance of histidine Eg =0.7 His) and its pharmaceutically acceptable acid addition salts.

and at a pH of 1.9 (formic acid/ acetic acid/ water 3. A polypeptide of the Formula 1V 0 ONE, S-R' OGIIJOII C611 nn 0 ONIIi S--I{ 3111 CH; (1112 IHz (IZHQ (IJH2 R"-NH-oH-c O-NH-(iJH-C ONII( 3HC 0-N1I-(i11-0 O-NI-I-(iII-C 0-NH(iH- o o Cys Tyr Phe Glu Asp Oys I! 1V NH; I I C}IZ ?H2 on, om CH; -NH-C ONH(|7H--C ONIICHa-C ONlIl Pro Orn Gly 15: 10:75) W of the distance of tryptophane i.9 y) wherein R denotes a radical capable of protecting a sulf- Total hydrolysis with 6 N hydrochloric acid for 16 hydryl radical in peptide synthesis and R denotes a hours at 110 C. and absence of air yields the expected radical capable of protecting an amino radical in peptide amino acids in the right ratio. synthesis.

9 4. A polypeptide of the Formula II ('1 ONE! (3H2 0 ONE; s R CH2CH2 CH2 CH2 CH2 CH2 1@ teinyl L-tyrosyl-L-phenyl-alanyl-L-glutaminy1-L-aspara- NHR" Gin Asp Oys Pro wherein R denotes a radical capable of protecting a sulfhydryl radical in peptide synthesis and R denotes a radical capable of protecting an amino radical in peptide synthesis.

5. L glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L- ornithyl-glycinamide.

6. The compound N carbobenzoxy-L-glutaminyl-L- asparaginyl S-benzyl-L-cysteinyl-L-prolyl-N-fi-p-toluenesulphonyl-L-ornithyl-glycinamide.

7. The compound N carbobenzoxy S henzyl-L-cys- Orn Gly 10 ginyl S benzyl-L-cysteinyl-L-prolyl-N-fi-p-toluenesulphonyl-L-ornithyl-glycinamide.

LEWIS GOTTS, Primary Examiner.

P. A. SMITH, Assistant Examiner. 

1. A COMPOUND SELECTED FROM THE GROUP CONSISTING OF A POLYPEPTIDE OF THE FORMULA 